Cargando…

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2

The proviral integration site for moloney murine leukemia virus 1 (Pim1) is a serine/threonine kinase and able to promote cell proliferation, survival and drug resistance. Overexpression of Pim1 has been observed in many cancer types and is associated with the poor prognosis of breast cancer. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bo-Wei, Huang, Chih-Hao, Liu, Liang-Chih, Cheng, Fang-Ju, Wei, Ya-Ling, Lin, Yueh-Ming, Wang, Yu-Fei, Wei, Ching-Ting, Chen, Yeh, Chen, Yun-Ju, Huang, Wei-Chien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276059/ https://www.ncbi.nlm.nih.gov/pubmed/34267653 http://dx.doi.org/10.3389/fphar.2021.614673

Ejemplares similares

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
por: Yang, Yun, et al.
Publicado: (2018)

Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells
por: Huang, Wei-Chien, et al.
Publicado: (2016)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
por: Chen, Zuhua, et al.
Publicado: (2022)

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER2 phosphorylation at Thr701
por: Chen, Chia‐Hung, et al.
Publicado: (2017)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy
por: Huang, Ping, et al.
Publicado: (2022)

miR‐221 confers lapatinib resistance by negatively regulating p27(kip1) in HER2‐positive breast cancer
por: Huynh, Thanh Kieu, et al.
Publicado: (2021)

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway
por: Kuo, Han-Peng, et al.
Publicado: (2013)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities
por: Sawaguchi, Yuichi, et al.
Publicado: (2021)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
por: Lei, Lei, et al.
Publicado: (2019)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer
por: Tsai, Chin-Hsien, et al.
Publicado: (2017)

Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
por: Shi, Hong-Zhi, et al.
Publicado: (2017)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
por: Wu, Xiaofan, et al.
Publicado: (2022)

Cardiovascular adverse effects associated with the use of anti-HER2 in breast cancer treatment
por: Valente, Patricia Marques Soares, et al.
Publicado: (2023)

Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κB
por: Ou, Chien-Chih, et al.
Publicado: (2012)

Bulleyaconitine A Exerts Antianxiety and Antivisceral Hypersensitivity Effects
por: Huang, Sheng-Nan, et al.
Publicado: (2020)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart
por: Klement, Giannoula L., et al.
Publicado: (2012)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro
por: Wang, Hongqian, et al.
Publicado: (2019)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression
por: Li, Zhenghu, et al.
Publicado: (2015)

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2012)

Hepatitis B Virus X Upregulates HuR Protein Level to Stabilize HER2 Expression in Hepatocellular Carcinoma Cells
por: Hung, Chao-Ming, et al.
Publicado: (2014)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

CuS@BSA-NB2 Nanoparticles for HER2-Targeted Photothermal Therapy
por: Ying, Ming, et al.
Publicado: (2022)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2jpj1aa18i4trugh0jk2sgva7u